Sarcoidosis affecting the lung parenchyma. It is characterized by the presence of non-necrotizing granulomas in the lung tissues. It is manifested with dyspnea, cough, fever, night sweats, fatigue, an...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on pulmonary sarcoidosis is limited due to its relatively rare occurrence and the complex nature of the disease, which affects fewer individuals worldwide. This rarity has resulted in fewer systematic clinical studies and a lack of comprehensive characterization of its clinical features and genetic underpinnings.
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Currently, there are several orphan drugs in development for pulmonary sarcoidosis, including Alidornase alfa, Aviptadil, and Humanized Recombinant Anti-Tumor Necrosis Factor Monoclonal Antibody, among others. Additionally, there are 33 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20sarcoidosis.
Actionable guidance for navigating care for pulmonary sarcoidosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on pulmonary sarcoidosis is limited due to its relatively rare occurrence and the complex nature of the disease, which affects fewer individuals worldwide. This rarity has resulted in fewer systematic clinical studies and a lack of comprehensive characterization of its clinical features and genetic underpinnings.
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Currently, there are several orphan drugs in development for pulmonary sarcoidosis, including Alidornase alfa, Aviptadil, and Humanized Recombinant Anti-Tumor Necrosis Factor Monoclonal Antibody, among others. Additionally, there are 33 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20sarcoidosis.
Actionable guidance for navigating care for pulmonary sarcoidosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on pulmonary sarcoidosis is limited due to its relatively rare occurrence and the complex nature of the disease, which affects fewer individuals worldwide. This rarity has resulted in fewer systematic clinical studies and a lack of comprehensive characterization of its clinical features and genetic underpinnings.
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Currently, there are several orphan drugs in development for pulmonary sarcoidosis, including Alidornase alfa, Aviptadil, and Humanized Recombinant Anti-Tumor Necrosis Factor Monoclonal Antibody, among others. Additionally, there are 33 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=pulmonary%20sarcoidosis.
Actionable guidance for navigating care for pulmonary sarcoidosis
To navigate your care effectively, consider seeking a pulmonologist with expertise in sarcoidosis. They can provide specialized insights into managing your condition. Additionally, you can explore clinical trials that may offer access to new therapies. A valuable resource for finding clinical trials is ClinicalTrials.gov. While there are currently no specific patient organizations identified for pulmonary sarcoidosis, staying connected with broader lung disease organizations may provide support and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.